We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is on ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...

Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day ...

This was the stock's third consecutive day of losses.

Amgen Inc. (NASDAQ:AMGN) is one of the top low volatility healthcare stocks to buy now. On July 23, BofA analyst Tim Anderson ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Topline The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the ...

Amgen is also a component of the Dow Jones Industrial Average and Nasdaq-100 index, making its shares highly liquid. Lastly, the biotech's annualized yield now sits at an all-time high.

Amgen won FDA approval for a cancer immunotherapy made from a genetically modified form of the cold sore virus. Here's how the drug could contribute to the rapidly growing field of immuno-oncology.